62 J ournal of Medicinal Chemistry, 2003, Vol. 46, No. 1
Wissner et al.
(13) Sweeney J r., W. E.; Chen, Y.; Nakanishi, K.; Frost, P.; Avner,
E. Treatment of Polycystic Kidney Disease with a Novel Tyrosine
Kinase Inhibitor. Kidney Int. 2000, 57, 33-40.
1H), 5.69 (s, 1H), 3.64 (m, 2H), 2.50 (m, 4H); Anal. (C24H21
ClFN5O2‚0.5H2O) C, H, N.
-
4-Tr im eth yla m m on iu m -bu t-2-en oic Acid [4-(3-Ch lor o-
4-flu or op h en yla m in o)-3-cya n o-7-et h oxyq u in olin -6-yl]-
a m id e Iod id e (53). To a warm solution of 0.52 g (1.1 mmol)
of 5 in 10 mL of THF was added 0.17 g (1.2 mmol) of CH3I.
After standing overnight in the refrigerator, the solution was
diluted with EtOAc. Solid was collected and washed with
EtOAc and ether giving 0.63 g (93%) of 53 as an off-white
powder: MS (ES+) m/z 482.2 (M+1).
(14) (a) Elder, J . T.; Fisher, G. J .; Lindquist, P. B.; Bennett, G. J .;
Pittelkow, M. R.; Coffey, R. J .; Ellingsworth, L.; Derynck, R.;
Voorhees, J . J . Overexpression of Transforming Growth Factor-R
in Psoriatic Epidermis. Science 1989, 243, 811-814. (b) Cook,
P. W.; Peipkorn, M.; Clegg, C. H.; Plowman, G. D.; DeMay, J .
M.; Brown, J . R.; Pittelkow, M. R. Transgenic Expression of the
Human Amphiregulin Gene Induces a Psoriasis-like Phenotype.
J . Clin. Invest. 1997, 100, 2286-2294.
(15) Davies, D. E.; Polosa, R.; Puddicombe, S. M.; Richter, A.; Holgate,
S. T. The Epidermal Growth Factor Receptor and its Ligand
Family: Their Potential Role in Repair and Remodelling in
Asthma. Allergy 1999, 54, 771-783.
(16) (a) Yamamoto, T.; Ikawa, S.; Akiyama, T.; Semba, K.; Nomura,
N.; Miyajima, N.; Saito, T.; Toyoshima, K. Similarity of Protein
Encoded by the Human c-erb-B-2 Gene to the Epidermal Growth
Factor Receptor. Nature 1986, 319, 230-234. (b) Coussens, L.;
Yang-Feng, T. L.; Liao, Y.-C.; Chen, E.; Gray, A.; McGrath, J .;
Seeburg, P. H.; Libermann, T. A.; Schlessinger, J .; Francke, U.;
Levinson, A.; Ullrich, A. Tyrosine Kinase Receptor with Exten-
sive Homology to EGF Receptor Shares Chromosomal Location
with neu Oncogene. Science 1985, 230, 1132-1139.
Ack n ow led gm en t. The authors wish to thank Drs.
Tarek Mansour, Philip Frost, J anis Upeslacis, and
Dennis Powell for their support and encouragement. We
also would like to thank the members of the Wyeth
Discovery Biology group for in vivo evaluations, and
members of the Wyeth Discovery Analytical Chemistry
group for analytical and spectral determinations.
Refer en ces
(17) Wissner, A.; Berger, D. M.; Boschelli, D. H.; Floyd, M. B. J r.,
Greenberger, L. M.; Gruber, B. C.; J ohnson, B. D.; Mamuya, N.;
Nilakantan, R.; Reich, M. F.; Shen, R.; Tsou, H.-R.; Upeslacis,
E.; Wang, Y.-F.; Wu, B.; Ye, F.; Zhang, N. 4-Anilino-6,7-
dialkoxyquinoline-3-carbonitrile Inhibitors of Epidermal Growth
Factor Receptor (EGF-R) Kinase and Their Bioisosteric Rela-
tionship to the 4-Anilino-6,7-dialkoxyquinazoline Inhibitors. J .
Med. Chem. 43, 2000, 3244-3256.
(18) (a) Fry, D. W.; Kraker, A. J .; McMichael, A.; Ambroso, L. A.;
Nelson, J . M.; Leopold , W. R.; Connors, R. W.; Bridges, A. J . A
Specific Inhibitor of the Epidermal Growth Factor Receptor
Tyrosine Kinase. Science 1994, 265, 1093-1095. (b) Ward, W.
H. J .; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.;
Green, L. R. Epidermal Growth Factor Tyrosine Kinase. Inves-
tigation of Catalytic Mechanism, Structure-Based Searching and
Discovery of a Potent Inhibitor. Biochem. Pharm. 1994, 48, 659-
666.
(19) (a) Wang, Y. D.; Miller, K.; Boschelli, D. H.; Ye, F.; Wu, B.; Floyd,
M. B.; Powell, D. W.; Wissner, A.; Weber, J . M.; Boschelli, F.
Inhibitors of Src Tyrosine Kinase: The Preparation and Struc-
ture-Activity Relationship of 4-Anilino-3-cyanoquinolines and
4-Anilinoquinazolines. Bioorg. Med. Chem. Lett. 2000, 10, 2477-
2480. (b) Boschelli, D. H.; Wang, Y. D.; Ye, F.; Wu, B.; Zhang,
N.; Dutia, M.; Powell, D. W.; Wissner, A.; Arndt, K.; Weber, J .
M.; Boschelli, F. Synthesis and Src Kinase Inhibitory Activity
of a Series of 4-Phenylamino-3-quinolinecarbonitriles. J . Med.
Chem. 2001, 44, 822-833. (c) Boschelli, D. H.; Ye, F.; Wang, Y.
D.; Dutia, M.; J ohnson, S. L.; Wu, B.; Miller, K.; Powell, D. W.;
Yaczko, D.; Young, M.; Tischler, M.; Arndt, K.; Discafani, C.;
Etienne, C.; Gibbons, J .; Grod, J .; Lucas, J .; Weber, J . M.;
Boschelli, F. Optimization of 4-Phenylamino-3-quinolinecarbo-
nitriles as Potent Inhibitors of Src Kinase Activity. J . Med.
Chem. 2001, 44, 3965-3977.
(20) (a) Zhang, N.; Wu, B.; Powell, D.; Wissner, A.; Floyd, M. B.;
Kovacs, E. D.; Toral-Barza, L.; Kohler, C. Synthesis and
Structure-Activity Relationships of 3-Cyano-4-(phenoxyanilino)-
quinolines as MEK (MAPKK) Inhibitors. Bioorg. Med. Chem.
Lett. 2000, 10, 2825-2828. (b) Zhang, N.; Wu, B.; Eudy, N.;
Wang, Y.; Ye, F.; Powell, D.; Wissner, A.; Feldberg, L. R.; Kim,
S. C.; Mallon, R.; Kovacs, E. D.; Toral-Barza, L.; Kohler, C. A.
MEK(MAPKK) Inhibitors. Part 2: Structure-Activity Relation-
ships of 4-Anilino-3-cyano-6,7-dialkoxyquinolines. Bioorg. Med.
Chem. Lett. 2001, 11, 1407-1410.
(1) Plowman, G. D.; Ullrich, A.; Shawver, L. K. Receptor Tyrosine
Kinases as Targets for Drug Intervention. Drug News Perspect.
1994, 7, 334-337.
(2) Salomon, D. S.; Brandt, R.; Ciadiello, F.; Normanno, N. Epider-
mal Growth Factor-related Peptides and Their Receptors in
Human Malignancies. Crit. Rev. Oncol. Haematol. 1995, 19,
183-232. (b) Gullick, W. J . Prevalence of Aberrant Expression
of the Epidermal Growth Factor Receptor in Human Cancers.
Br. Med. Bull. 1991, 47, 87-98. (c) Woodburn, J . R. The
Epidermal Growth Factor Receptor and its Inhibition in Cancer
Therapy. Pharmacol. Ther. 1999, 82, 241-250.
(3) (a) Ekstrand, A. J .; Sugawa, N.; J ames, C. D.; Collins, V. P.
Amplified and Rearranged Epidermal Growth Factor Receptor
Genes in Human Glioblastomas Reveal Deletions of Sequences
Encoding Portions of the N- and/or C-Terminal Tails. Proc. Natl.
Acad. Sci. U.S.A. 1992, 89, 4309-4313. (b) Wikstrand, C. J .;
McLendon, R. E.; Friedman, A.; Bigner, D. D. Cell Surface
Localization and Density of the Tumor-associated Variant of the
Epidermal Growth Factor Receptor, EGFRvIII. Cancer Res.
1997, 57, 4130-4140.
(4) Olapade-Olaopa, E. O.; Moscatello, D. K.; MacKay, E. H.;
Horsburgh, T.; Sandhu, D. P. S.; Terry, T. R.; Wong, A. J .; Habib,
F. K. Evidence for the Differential Expression of a Variant EGF
Receptor Protein in Human Prostate Cancer. Br. J . Cancer 2000,
82, 186-194.
(5) Moscatello, D. K.; Holgado-Mudruga, M.; Godwin, A. K.; Ramirez,
G.; Gunn, G.; Zoltick, P. W.; Biegel, J . A.; Hayes, R. L.; Wong,
A. J . Frequent Expression of a Mutant Epidermal Growth Factor
Receptor in Multiple Human Tumors. Cancer Res. 1995, 55,
5536-5539.
(6) Garcia de Palazzo, I. E.; Adams, G. P.; Sundareshan, P.; Wong
A. J .; Testa, J . R.; Bigner, D. D.; Weiner L. M. Expression of
Mutated Epidermal Growth Factor Receptor by Nonsmall Cell
Lung Carcinomas. Cancer Res. 1993, 53, 3217-3220.
(7) Ekstrand, A. J .; Longo, N.; Hamid, M. L.; Olson, J . J .; Liu, L.;
Collins, V. P.; J ames, C. D. Functional Characterization of an
EGF Receptor with
a Truncated Extracellular Domain Ex-
pressed in Glioblastomas with EGFR Gene Amplification. On-
cogene 1994, 9, 2313-2320.
(8) Cohen, D. W.; Simak, R.; Rair, W. R.; Melamed, J .; Scher, H. I.;
Cordon-Cardo, C. Expression of Transforming Growth Factor-
alpha and the Epidermal Growth Factor Receptor in Human
Prostate Tissues. J . Urol. 1994, 152, 2120-2124.
(9) Grandis, J . R.; Melhem, M. F.; Gooding, W. E.; Day, R.; Holst,
V. A.; Wagener, M. M.; Drenning, S. D.; Tweardy, D. J . Levels
of TGFR and EGFR Protein in Head and Neck Squamous Cell
Carcinoma and Patient Survival. J . Natl. Cancer Inst. 1998, 90,
824-832.
(10) Morishigie, K. I.; Kurachi, H.; Ameniya, K.; Fujita, Y.; Yama-
moto, T.; Mikaye, A.; Tanizawa, O. Evidence for the Involvement
of TGFR and EGFR Autocrine Mechanism in Primary Ovarian
Cancers In Vitro. Cancer Res. 1991, 51, 5322-5328.
(11) Rusch, V.; Klimstra, D.; Venkatraman, E.; Pisters, P. W. T.;
Langenfeld, J .; Dmitrovsky, E. Overexpression of the Epidermal
Growth Factor Receptor and its Ligand Transforming Growth
Factor Alpha is Frequent in Resectable Nonsmall Cell Lung
Cancer but does not Predict Tumor Progression. Clin. Cancer
Res. 1997, 3, 515-522.
(21) (a) Wissner, A.; J ohnson, B. D.; Floyd, M. B.; Kitchen, D. B.
4-Aminoquinazolines as EGFR inhibitors. U.S. Patent 5760041,
1998. (b) Discafani, C. M.; Carroll, M. L.; Floyd, M. B. J r.;
Hollander, I. J .; Husain, Z.; J ohnson, B. D.; Kitchen, D.; May,
M. K.; Malo, M. S.; Minnick, A. A. J r.; Nilakantan, R.; Shen, R.;
Wang, Y.-F.; Wissner, A.; Greenberger, L. M. Irreversible
Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase
with in vitro Activity by N-[4-[(3-Bromophenyl)amino]-6-quinazoli-
nyl]-2-butynamide (CL-387785). Biochem. Pharmacol. 1999, 57,
917-925.
(22) Fry, D. W.; Bridges, A. J .; Denny, W. A.; Doherty, A.; Gries, K.
D.; Hicks, J . L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo,
J . A.; McNamara, D. J .; Nelson, J . M.; Sherwood, V.; Smaill, J .
B.; Trumpp-Kallmeyer, S.; Dobrusin, E. M. Specific, Irreversible
Inactivation of the Epidermal Growth Factor Receptor and
ErbB2, by a New Class of Tyrosine Kinase Inhibitor. Proc. Natl.
Acad. Sci. U.S.A. 1998, 95, 12022-12027.
(12) Thogersen, V. B.; J orgensen, P. E.; Sorensen, B. S.; Bross, P.,
Orntoft, T.; Wolf, H.; Nexo, E. Expression of Transforming
Growth Factor Alpha and Epidermal Growth Factor Receptor
in Human Bladder Cancer. Scand. J . Clin. Lab Invest. 1999,
59, 267-277.